Key challenge associated with the management of HR+/HER2- breast cancer

Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Gu...Подробнее

Outlook for HR+/HER2- advanced breast cancer treatmentПодробнее

HER2 Low Breast Cancer A New Therapeutic Subtype | 2023 KU Breast Cancer Year in Review ConferenceПодробнее

Dr. Yardley on Challenges With Resistance Mechanisms in HR+/HER2- Breast CancerПодробнее

Management of premenopausal HR+/HER2- breast cancer with micro-metastasisПодробнее

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast CancerПодробнее

Important considerations in the management of HR+, HER2-negative early breast cancerПодробнее

Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancerПодробнее

Recent Updates in HR-Positive/HER2-Negative Early Breast Cancer: A Deep Dive Into Understanding t...Подробнее

Advanced Breast Cancer: Challenges in Pathways DevelopmentПодробнее

Dr. Janni on Challenges Facing the Treatment of HER2-Positive Breast CancerПодробнее

Dr Sara M. Tolaney: Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast CancerПодробнее

Dr. Pegram on Challenges Facing the Treatment of HER2-Positive Breast CancerПодробнее

Dr. Geyer Discusses Challenges in HER2-Positive Metastatic Breast Cancer ManagementПодробнее

The challenges of treatment sequencing in HR+ breast cancer patientsПодробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее

Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancerПодробнее

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment ArsenalПодробнее

Dr. Hamilton Discusses Challenges With Approved Treatments for HER2-Positive Breast CancerПодробнее